Despite many advances in medicine, cancer remains the most common cause of death in Germany and the Western World. The further development of diagnostic tests and treatment is not only essential for individual patients, but also represents an enormous challenge to our public health care system. Scientists in Cologne led by Prof. Christian Reinhardt have identified a new approach to targeted cancer therapy.
Through the molecular characterization of tumor cells, Prof. Christian Reinhardt and his team of scientists at the University of Cologne and CECAD have developed a new approach to treating cancer.
“These new findings offer a novel molecular approach to treating genetically-defined cancers more effectively in the future,” says Prof. Reinhardt, lead scientist of this new study, of the recent research success. An international team of scientists from Germany, Denmark and England was involved in the study, which has been published today in the high impact journal Cell.
In the Department of Internal Medicine I at the University of Cologne, Prof. Reinhardt leads a research group that is substantially sponsored by the German Research Foundation (DFG), teh German Cancer Aid, and the Volkswagen Foundation.
With the aid of a new screening procedure, the research team has tested the efficacy of various compounds and, in particular, of novel compound combinations. Analytical results showed that tumor cells and cancers with a mutation in the KRAS gene depend on two distinct enzymes (Chk1 and MK2). The KRAS gene is one of the most commonly mutated genes appearing in human cancer cells.
Mutated KRAS is found in almost all pancreatic cancers, and about one-third of lung and colorectal cancers. Detailed analyses showed that KRAS mutations lead to massively increased cell growth. But the very rapid proliferation of cancer cells causes problems: DNA duplication that has to take place prior to every cell division is much more difficult for cancer cells under conditions of accelerated growth.
The latest data from the Cologne scientists show that KRAS-mutated cancer cells rely on MK2 and Chk1 enzyme function for error-free duplication of their DNA. This dependence on MK2 and Chk1 distinguishes KRAS-mutant cancer cells from healthy tissue, which is capable of duplicating DNA without these particular enzymatic functions.
And the new therapeutic approach is based on this very difference between cancer cells and normal tissue. The research team has shown that tumor cells and cancers with KRAS mutations respond very well to combination therapy with Chk1 and MK2 inhibitors. Normal tissue, on the other hand, tolerates the combination therapy well and has very little in the way of adverse reactions.
Taking a closer look at these enzymes, Chk1 and MK2 are protein kinases. In the last 10 years, this particular enzyme group has increasingly come to the attention of the big pharmaceutical companies. Enzymes can potentially be inhibited and therefore provide options for developing new therapeutic agents.
The combined pharmacological inhibition of Chk1 and MK2 is a therapeutic strategy that could be used specifically for treating KRAS-mutated cancers. “Chk1/MK2 inhibition works specifically in KRAS-mutant cancer cells. Normal tissue isn’t really affected, because healthy cells don’t contain KRAS genes that have undergone mutation,” explains Dr. Felix Dietlein, lead author of the publication, when describing the therapeutic concept.
Prof. Michael Hallek, Head of the Department of Internal Medicine I at the University of Cologne, finds the new therapeutic approach very promising. “MK2 is a protein kinase that has been investigated in depth for some time, as its function seems to have a role in the development of rheumatoid disease.
The protein kinase Chk1 has also been closely scrutinized in recent years, and the first clinical trials of various Chk1 inhibitors are now underway. These fascinating findings may provide treating physicians with an effective new tool for treating KRAS-mutant cancers in the near future,” he confirms.
Even though they have been the subject of research and development as medicinal products for some time, none of the MK2 inhibitors has yet obtained regulatory approval. Work on this project was generously sponsored by the German Research Foundation (DFG), German Cancer Aid, and the Volkswagen Foundation.
For CECAD and the University Hospital Cologne, the development of this new therapeutic approach represents a significant and promising opportunity: additional treatment options for the fight against cancer in the near future – an important aspect of aging research at the Cluster of Excellence.
Prof. Christian Reinhardt
CECAD, University of Cologne
Department of Internal Medicine I
Cologne University Hospital
Phone +49 221 478-96701
Astrid Bergmeister MBA
Head of CECAD PR & Marketing
University of Cologne
Phone + 49 (0) 221-478 84043
Astrid Bergmeister | idw - Informationsdienst Wissenschaft
Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction